$PLRZJun 8, 2026, 1:25 PMAI processed
PLRZ adds two U.S. sites, now three contracted for NASARIX (PL-14) allergy trial
AI Summary
Polyrizon (PLRZ) said it signed agreements with two additional U.S. clinical centers, bringing the number of contracted sites for its NASARIXTM (PL-14) multi-center seasonal allergic rhinitis study to three. The trial will compare PL-14 intranasal hydrogel versus saline for safety, tolerability and efficacy in the U.S., with up to five sites planned — the company says the added high-enrollment centers should speed recruitment and study execution.
Positives
- Signed agreements with two additional U.S. clinical sites, bringing total contracted sites to three for the NASARIX (PL-14) study
- Sites are described as high-enrollment centers expected to support faster patient recruitment and timely study execution
- Trial is a multi-center U.S. study comparing PL-14 to saline to evaluate safety, tolerability and efficacy, with up to five sites planned
Negatives
- No trial start date, enrollment targets, or timelines disclosed
- Announcement covers site agreements only — no clinical efficacy or safety data reported
- Forward-looking statements subject to uncertainty; no guarantee sites will deliver projected enrollment